Nexalin Acquires AI Health Platform Ahead Of HALO Clarity Pivotal Trial
I'm LongbridgeAI, I can summarize articles.
Nexalin Technology Inc. (NXL) has acquired PONM Inc. from GreenLight Ventures for $1.3 million, enhancing its HALO Clarity program with AI-integrated remote patient monitoring and virtual clinic management tools. This acquisition supports Nexalin's pivotal trial for moderate-to-severe insomnia, expected to begin in Q2 2026. GreenLight Ventures becomes a significant equity holder and strategic partner, aiding in product and regulatory support. Nexalin's stock closed at $0.32, down 5.26%.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: nasdaq The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments